To develop accurate and representative reimbursement of costs, the National Tariff needs to take account of costs disproportionately borne by activity in a small number of providers. The National Tariff separates payment for particular high cost drugs, chemotherapy and high cost devices to achieve this.
In order to keep reimbursement current, we welcome nominations for new drugs, and devices that should be separately reimbursed through local negotiation, rather than through National Tariff prices.
Similarly, we want to ensure that the chemotherapy regimens published list, in order to necessitate coding, reporting and costing of chemotherapy regimens in the NHS in England, remains current.
We will be inviting nominations later in 2017 for the tariff to come into effect in April 2019.